Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 6—June 2005
Letter

Quinolone Safety and Efficacy

On This Page
Article Metrics

Cite This Article

To the Editor: Richard Frothingham should be commended for providing added perspective on the matter of quinolone selection. His letter to the editor emphasizing the paramount importance of a well-established safety profile and documented clinical efficacy in severe infections before a "wholesale change" to the newer quinolones is an appropriate response to Michael Scheld's essay on maintaining quinolone class efficacy in which a "correct spectrum" strategy of using the most potent quinolone to treat the presumed or confirmed pathogen was described and advocated (1). In his article, Frothingham reminds us that serious adverse drug effects in patients led to the withdrawal or restriction of 4 quinolones in the last decade and that safety may differ substantially among the quinolones discussed in Scheld's review (ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin) (2).

With the exception of labeling changes regarding glucose homeostasis abnormalities associated with gatifloxacin therapy, the subject of quinolone safety is centered on torsades de pointes. Data published in 2001 are cited; these consist of a review of crude rates of US cases of torsades de pointes from January 1996 through May 2, 2001 (3). However, these data only capture adverse drug reports for the first full year gatifloxacin and moxifloxacin were widely available in the United States. The last several years have seen dramatic uptake of all 3 respiratory quinolones. Use of these agents is pervasive in both community and hospital settings. Indeed, the Infectious Diseases Society of America, American Thoracic Society, and Sinus and Allergy Health Partnership have since published revised consensus statements calling for the use of these agents earlier in therapy for community-acquired pneumonia and bacterial sinusitis (46).

December 2004 marked 5 years since the Food and Drug Administration approved gatifloxacin and moxifloxacin and 8 years since the approval of levofloxacin. As a result of tens of millions of patient exposures, we now have more robust data to work with and are better able to make informed and meaningful safety comparisons, particularly with respect to torsades de pointes, a rare, life-threatening cardiac arrhythmia infrequently associated with quinolone therapy.

With respect to efficacy, Frothingham writes that ciprofloxacin and levofloxacin have been studied in patient populations with more severe illness, and trials of the newer quinolones have enrolled patients with predominantly mild or moderate community-acquired infections and low overall death rates in comparison. However, a cursory review of the literature suggests otherwise. As with gatifloxacin and moxifloxacin, few peer-reviewed, published data support the use of levofloxacin in the treatment of severe, life-threatening infections at the currently approved doses of 500 mg or 750 mg.

Indeed, the 2 references cited raise serious concern about the suitability of levofloxacin at currently recommended doses for severe and life-threatening infections. In File et al. (7) levofloxacin was studied in only 16 patients classified as having severe community-acquired pneumonia; in Norrby et al. (8) a dose of levofloxacin 500 mg every 12 hours was studied in severe community-acquired pneumonia. At this time, other published studies support the use of levofloxacin at a dose of 500 mg every 12 hours in severe and life-threatening infections: an approved regimen in Europe but not yet approved in the United States (9,10).

In summary, differences in quinolone safety are evidenced by labeling changes to gatifloxacin, the only quinolone to carry a specific warning regarding glucose homeostasis abnormalities. However, the incidence of torsades de pointes associated with each of these agents is ripe for further investigation as we pass the 5-year mark of approval for the new respiratory quinolones. An update of those data on the rate of torsades cited by Frothingham and published in 2001 would provide meaningful guidance to clinicians. Currently, with the exception of ciprofloxacin, each of these quinolones contains labeling guidance in the form of a warning (gatifloxacin, moxifloxacin) or a precaution (levofloxacin), and concurrent use with class IA (e.g., quinidine, procainamide) or class III (e.g., amiodarone, sotalol) antiarrhythmics should be avoided to reduce the risk of torsades de pointes per current product labeling.

Ciprofloxacin remains the only quinolone to date based on multiple, head-to-head, well-controlled, published trials to have established efficacy and safety in a severely ill patient population at approved doses. A paucity of published clinical data exist on the use of gatifloxacin, levofloxacin and moxifloxacin in hospitalized patients with severe, life-threatening infections. Therefore, the respective manufacturers must establish safety and efficacy in well-controlled studies with the resultant data made available in peer-reviewed journals before these agents are fully embraced for these infections.

Top

Spartaco Bellomo*Comments to Author 

Author affiliation: *Christ Hospital, Jersey City, New Jersey, USA

Top

References

  1. Scheld  WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis. 2003;9:19.PubMed
  2. Frothingham  R. Quinolone safety and efficacy more important than potency. Emerg Infect Dis. 2004;10:1567.PubMed
  3. Frothingham  R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy. 2001;21:146872. DOIPubMed
  4. Mandell  LA, Bartlett  JG, Dowell  SF, File  TM Jr, Musher  DM, Whitney  C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis. 2003;37:140533. DOIPubMed
  5. Niederman  MS, Mandell  LA, Anzueto  A, Bass  JB, Broughton  WA, Campbell  GD, Guidelines for the management of adults with community-acquired pneumonia. Am J Respir Crit Care Med. 2001;163:173054.PubMed
  6. Anon  JB, Jacobs  MR, Poole  MD, Ambrose  PG, Benninger  MS, Hadley  JA, Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg. 2004;130(Suppl):145.PubMed
  7. File  TM Jr, Segreti  J, Dunbar  L, Player  R, Kohler  R, Williams  RR, A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother. 1997;41:196572.PubMed
  8. Norrby  SR, Petermann  W, Willcox  PA, Vetter  N, Salewski  E. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis. 1998;30:397404. DOIPubMed
  9. Geddes  A, Thaler  M, Schonwald  S, Harkonen  M, Jacobs  F, Nowotny  I. Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial. J Antimicrob Chemother. 1999;44:799810. DOIPubMed
  10. Pea  F, Di Qual  E, Cusenza  A, Brollo  L, Baldassarre  M, Furlanut  M. Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. Clin Pharmacokinet. 2003;42:58998. DOIPubMed

Top

Cite This Article

DOI: 10.3201/eid1106.040740

Related Links

Top

Table of Contents – Volume 11, Number 6—June 2005

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Spartaco Bellomo, Christ Hospital, Division of Infectious Diseases, 142 Palisade Ave, Jersey City, NJ 07306, USA; fax: 201-653-6697

Richard Frothingham, Duke Human Vaccine Institute, Duke University Medical Center Box 3258, Room 124 SORF, LaSalle St Extension, Durham, NC 27710, USA; fax: 919-684-4288

Send To

character(s) remaining.

Comment submitted successfully, thank you for your feedback.

Top

Page created: April 24, 2012
Page updated: April 24, 2012
Page reviewed: April 24, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external